HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Irving Vidaurre Selected Research

Har(29)- Arg(28) Nle(27) Orn(21) His(20) Orn(12,) Abu(15) His(11) Tyr(Me)(10) Har(9) Ala(8) Fpa(5,6) Arg(2) (PhAc-Ada)(0)-Tyr(1) GHRH(1-29)NH2

1/2022Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
1/2018Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
1/2014Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
9/2012Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
2/2012Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
11/2010The effect of GHRH antagonists on human glioblastomas and their mechanism of action.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Irving Vidaurre Research Topics

Disease

19Neoplasms (Cancer)
01/2022 - 10/2009
6Glioblastoma (Glioblastoma Multiforme)
01/2022 - 07/2010
4Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
02/2013 - 03/2011
3Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 07/2010
3Lung Neoplasms (Lung Cancer)
11/2018 - 09/2017
3Neoplasm Metastasis (Metastasis)
12/2013 - 07/2010
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2018 - 01/2018
2Myocardial Infarction
09/2017 - 01/2015
1Colorectal Neoplasms (Colorectal Cancer)
01/2022
1Edema (Dropsy)
09/2017
1Body Weight (Weight, Body)
11/2015
1Diabetes Mellitus
11/2015
1Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
11/2015
1Heart Failure
01/2015
1Melanoma (Melanoma, Malignant)
01/2014
1Pancreatic Neoplasms (Pancreatic Cancer)
05/2013
1Liver Neoplasms (Liver Cancer)
10/2012
1Breast Neoplasms (Breast Cancer)
09/2012
1Triple Negative Breast Neoplasms
09/2012
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2012
1Lower Urinary Tract Symptoms
04/2012
1Adenocarcinoma
02/2012
1Acromegaly
01/2012
1Adenoma (Adenomas)
01/2012
1Prostatic Neoplasms (Prostate Cancer)
03/2011
1Colonic Neoplasms (Colon Cancer)
10/2009

Drug/Important Bio-Agent (IBA)

12Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA
11/2018 - 10/2009
6Har(29)- Arg(28) Nle(27) Orn(21) His(20) Orn(12,) Abu(15) His(11) Tyr(Me)(10) Har(9) Ala(8) Fpa(5,6) Arg(2) (PhAc-Ada)(0)-Tyr(1) GHRH(1-29)NH2IBA
01/2022 - 11/2010
6Gonadotropin-Releasing Hormone (GnRH)FDA Link
11/2018 - 05/2011
6somatotropin releasing hormone receptorIBA
11/2018 - 01/2012
6Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2018 - 03/2011
3Peptides (Polypeptides)IBA
09/2017 - 03/2011
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2014 - 07/2012
3lysine(6)-doxorubicin LHRHIBA
05/2013 - 07/2012
3CytokinesIBA
03/2013 - 05/2011
3PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2IBA
04/2012 - 10/2009
2Gonadal Steroid Hormones (Sex Hormones)IBA
11/2018 - 05/2013
2CyclinsIBA
11/2018 - 01/2018
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2013 - 02/2012
2LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
03/2013 - 07/2012
2Gastrin-Releasing PeptideIBA
02/2013 - 10/2012
2Proteins (Proteins, Gene)FDA Link
10/2012 - 01/2012
2NeuropeptidesIBA
09/2012 - 04/2012
2cetrorelix (Cetrotide)FDA Link
04/2012 - 05/2011
2matrigelIBA
02/2012 - 07/2010
1Antineoplastic Agents (Antineoplastics)IBA
01/2022
1(N-acetyl-tyr1,D-arg2)fragment 1-29 amideIBA
11/2018
1Cyclin-Dependent Kinases (cdk Proteins)IBA
11/2018
1CateninsIBA
01/2018
1Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA
01/2018
1Cadherins (E-Cadherin)IBA
01/2018
1Neurotransmitter Agents (Neurotransmitter)IBA
09/2017
1N-Me-Tyr1,D-Ala2,Asn8,Arg29-NHCH3-JI-38IBA
11/2015
1Glucose (Dextrose)FDA LinkGeneric
11/2015
1Insulin (Novolin)FDA Link
11/2015
1Streptozocin (Streptozotocin)FDA Link
11/2015
1Therapeutic UsesIBA
11/2015
1Pharmaceutical PreparationsIBA
01/2014
1MIA-690IBA
01/2014
1Dihydrotachysterol (AT 10)IBA
01/2014
1SynucleinsIBA
12/2013
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
12/2013
1Tumor Biomarkers (Tumor Markers)IBA
12/2013
1Metalloproteases (Metalloproteinases)IBA
12/2013
1Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA
12/2013
1S100 Calcium-Binding Protein A4IBA
12/2013
1CD146 AntigenIBA
12/2013
1Hca(6)-Leu(13)-psi(CH2N)-Tac(14)- bombesin(6-14)IBA
10/2012
1BombesinIBA
10/2012
1Growth Hormone (Somatotropin)IBA
09/2012
1Hormones (Hormone)IBA
09/2012
1Testosterone (Sustanon)FDA Link
04/2012
1AndrogensIBA
04/2012
1ImmunosorbentsIBA
02/2012
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
02/2012
1LigandsIBA
02/2012
1EnzymesIBA
02/2012
1JV 1-36IBA
01/2012
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2012
1MZ 4-71IBA
01/2012
1vapreotideIBA
01/2012
1endonuclease GIBA
11/2010
1Apoptosis Inducing FactorIBA
11/2010
1Cytochromes c (Cytochrome c)IBA
11/2010
1Estrogens (Estrogen)FDA Link
07/2010
1Fibronectins (Fibronectin)IBA
07/2010

Therapy/Procedure

7Therapeutics
01/2022 - 07/2010
1Drug Therapy (Chemotherapy)
01/2014
1Aftercare (After-Treatment)
11/2010